
View larger version (87K):
[in this window]
[in a new window]
|
Fig. 3. Myf5 requirement differs between somitic, head and fin muscle
development. In situ mRNA hybridisation and/or MyHC immunohistochemistry
of control and morphant wild-type or myf5+/hu2022 incross
embryos. Dorsal flatmounts with anterior to top (A,F), or whole-mounts with
anterior to left in ventral (B, upper row, C,D), lateral (B, lower row) or
dorsal (E) view. (A) myf5hu2022 mutants injected
with myod MO show a loss of the adaxial slow muscle differentiation
markers smyhc1, actin, tpma and mef2ca and MyHC
immunostaining (black arrows), but retain other adaxial markers such as
prdm1 and ptc1 (white arrows). (B-D) Head muscles are
present in 80 hpf myf5hu2022 mutants but are missing from
embryos injected with myod (B,C) or myog MO (C). Arrowheads
indicate lack of ventral (green), dorsal (yellow), extra-ocular (red) and
sternohyoideus (sh, white) muscles. All embryos show normal heart (h, blue
arrow). Note the presence of sternohyoideus in myog morphants. All
embryos from a myf5+/hu2022 incross have normal expression
of myhz1 at 72 hpf (C) and myog at 48 hpf (D) in the head.
myod morphants lack myog mRNA (19/21), although
sternohyoideus was still detected in some embryos (6/21). (E) In
pectoral fin, myog mRNA in muscle masses (pink arrowheads) and MyHC
are ablated or reduced by loss of Myod, but not by loss of Myf5. Ibx2
mRNA is unaffected by myod MO. (F) Expression of
hsp90a is delayed in fast muscle precursors (arrow) of the
myf5hu2022 mutant and recovers in somites (arrowhead), but
is drastically reduced throughout the axis in
myf5hu2022 mutants injected with myod
MO, both in slow and fast precursors. meox1 expression is unchanged
in fast precursors.
|